We have previously demonstrated that liposomes generated from poly(cationic lipid) (PCL) and cholesterol (Chol) have low cytotoxicity, are serum resistant, and display a transfection efficiency in vitro similar to commercially available cationic liposomes. Our in vivo experiments demonstrated that PCL-Chol liposomes bound much less avidly to serum proteins than did liposomes composed of 1,2-bis(dioleoyloxy)-3-(trimethylamonio)propane (DOTAP)-Chol or DO-TAP-L-a dioleoyl phosphatidylethanolamine (DOPE). Injection of the lipoplexes (PCL-Chol+DNA) through the portal vein after partial hepatectomy (PH) led to much higher reporter gene expression (luciferase) in the liver than did naked DNA injection. Marked green fluorescent protein expression was visualized in almost all hepatocytes in the liver of mice receiving lipoplex injection, even in the absence of PH. Subcutaneous injection of thyroid hormone triiodothyromine (T 3 ) significantly promoted hepatocyte regeneration and markedly enhanced PCL-Chol-mediated gene transfer in mouse liver when the lipoplex was administrated through either portal or tail vein. With T 3 pretreatment, PCL-Chol exerted a better gene transfer efficacy in mouse liver than DOTAP-Chol or DOTAP-DOPE. Two injections of lipoplexes through an indwelling catheter in the portal vein extended the transgene expression at a high level when T 3 injection was repeated. In conclusion, our findings demonstrate that the polymerized cationic liposomes are very stable in the blood and are effective agents for in vivo gene delivery, and that thyroid hormone administration offers a noninvasive approach to enhance liposome-mediated liver gene delivery.
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Introduction
Cationic liposomes are widely used for gene transfection in vitro and have been tested for gene delivery to the liver. [1] [2] Templeton et al showed that cationic liposomes generated from 1,2-bis(dioleoyloxy)-3-(trimethylamonio)propane (DOTAP) and cholesterol (Chol) were effective gene transfer agents in vivo. 2 This formulation of the cationic liposomes was improved and recently employed to deliver a tumor suppressor gene for the treatment of human lung cancer. 3 A recent study showed that direct intratumoral injection of liposome-DNA to implanted hepatocellular carcinoma in nude mice led to a high level of transgene expression. 4 However, critical issues still exist in cationic liposome-mediated gene delivery to the liver. For example, the efficiency of gene delivery is compromised due to the formation of aggregates between cationic lipids and serum proteins bearing negative charges (albumin, lipoprotein, etc). Other issues include the administration routes of liposome-DNA complexes (lipoplex), the proliferation state of cells to be transfected, and obtaining extended transgene expression. To address the first challenge, Saravolac et al 5 incorporated amphiphilic polyethylene glycol (PEG) into cationic lipids to shield the charges of lipoplex and to provide a means of steric protection. Others have tried various types of polymers, such poly(L-lysine), [6] [7] poly(ethyleneimine), [8] [9] poly(methacrylate) 10 and polyamidoamine dendrimers. 11, 12 To cope with this problem, we have recently described methods for the polymerization of a novel cationic acrylamide lipid and reconstitution of the resultant poly(cationic lipid) (PCL) to yield stable cationic vesicles. 13, 14 We have studied extensively the toxicity, stability and gene transfection of the polymerized cationic liposomes generated from PCL and cholesterol (PCL-Chol).
14 Our findings demonstrated that PCL and PCL-Chol are serum resistant since the liposome size distribution did not change significantly when exposed to high serum concentration for a prolonged period. The serumresistant PCL and PCL-Chol also have little or no cytotoxicity to hepatocytes and Hep G 2 cells, and display a transfection efficiency in hepatoma cell lines similar to commercially available agents, such as Lipofectamine
In the present study, we report that PCL-Chol bound much less to plasma proteins in comparison to DOTAPChol or DOPAT-L-a dioleoyl phosphatidylethanolamine (DOPE) when administered intravenously. We also found that injection of the polymerized PCL-Cholplasmid DNA complexes through the portal vein achieved much higher transgene expression in the liver after partial hepatectomy than naked DNA, and that injection of thyroid hormone prior to the lipoplex administration enhanced hepatocyte regeneration and promoted PCL-Chol liposome-mediated gene delivery to the liver. Moreover, repeated injections of lipoplexes through an indwelling catheter in the portal vein extended the transgene expression in the liver at a high level.
Results
Binding to serum proteins of cationic liposomses and their biodistribution
In order to further confirm that PCL is serum resistant, we generated three formulations of cationic liposomes: PCL-Chol (3:1 molar ratio), DOTAP-Chol (3:1 molar ratio) and DOTAP-DOPE (3:1 molar ratio). The liposomes were labeled with [ 3 H]-cholesterol. Three mice at each time point were injected intravenously via tail vein with 200 ml of liposome suspension. Animals were killed 30, 120 and 240 min after the injection for collection of blood, liver, heart, lungs, spleen and kidneys. Red blood cells (RBC) were separated from the plasma and proteins in the plasma were precipitated by 50% trichloroacetic acid (TCA). The radioactivity in RBC, plasma and precipitated proteins from 600 ml of blood, homogenates of the liver, lungs, spleen and kidneys was determined, and the data are shown in Figure 1 . None of these three formulations bound appreciably to RBC during the first 4 h after the intravenous injection of cationic liposomes. Radioactivity in plasma isolated from mice injected with DOTAP-Chol or DOTAP-DOPE was 19-and 21-fold at 30 min, 8-and 12-fold at 120 min, 7-and 6-fold at 240 min higher than from mice injected with PCL-Chol (Po0.01), indicating an earlier clearance of PCL-Chol liposomes from the plasma (Figure 1, upper panel) . Moreover, the radioactivity in precipitated proteins from the plasma isolated from mice injected with DOTAPChol or DOTAP-DOPE was 22-or 23-fold at 30 min, 8-and 13-fold at 120 min, 7-and 5-fold at 240 min higher than from PCL-Chol-injected mice (Po0.01) (Figure 1 , middle panel). These findings indicate that PCL-Chol bound least to serum proteins in comparison to two commonly used cationic liposome formulations: DO-TAP-Chol or DOTAP-DOPE. Radioactivity (cpm/ 100 mg tissue) in the liver from mice injected with PCL-Chol was significantly higher than from those injected with DOTAP-Chol or DOTAP-DOPE during the first 4 h (Po0.05-0.01) (Figure 1, lower panel) . There was no significant difference in radioactivity (cpm/ 100 mg tissue) of the lungs, heart, spleen and kidneys from mice injected with these three formulations of cationic liposomes (data not shown).
PCL-mediated delivery of reporter genes to the liver Based on our in vitro experimental findings that a low charge ratio had a better transfection efficiency, we generated PCL-Chol liposomes with a 3:1 molar ratio, and complexed the lipids with plasmid DNA at a charge ratio of 1:1. These lipoplexes are stable and can be injected in a volume of 200-300 ml via tail vein or portal vein in mice. For our goal of liver gene delivery, we injected the lipoplex via the portal vein. The plasmid DNA used was either pEGFP-C1 or pNDLux.2 for these experiments. Two days after injection of 100 mg naked plasmid DNA (pEGFP-C1) through the portal vein, the frozen liver sections were examined. A faint image of GFP expression was visualized in the portal zone (Figure 2a ). However, with injection of the same amount of DNA with PCL-Chol liposomes, an extensive GFP image was observed in almost all hepatocytes, as well as in other cell types in the liver (Figure 2b ). GFP expression was also found in the spleen, lungs and kidneys, but with much less intensity.
In order to quantitate the extent of transgene expression, we used a plasmid vector, pNDLux.2, which encodes for firefly luciferase under the control of a cytomegalovirus (CMV) promoter. We also compared the gene delivery efficiency of portal vein injection versus tail vein injection of the lipoplex. To achieve a higher level of transgene expression in the liver, we performed partial hepatectomy to stimulate the hepatocyte proliferation in mice. The lipoplexes were injected 2 days after the partial hepatectomy (60-70% of the liver was dissected). The reporter gene expression in the liver, lungs, spleen and Figure 3 that the administration of PCLChol-DNA lipoplexes via tail vein resulted in a higher level of luciferase activity in the lungs than in the liver, and that portal vein injection enhanced the luciferase activity in the liver approximately 10-fold compared to that by tail vein injection. There was no significant change in the level of luciferase expression in the spleen or kidneys. Thus, portal vein injection of the lipoplex reversed the pattern of transgene expression in the liver and lungs. Partial hepatectomy strikingly promoted the transgene expression by both routes of lipoplex administration (14-fold increase for tail vein injection and 83.3-fold increase for portal vein injection) without significantly changing the expression in the lungs. The lipoplex injection via portal vein after partial hepatectomy achieved a 135-fold increase in luciferase activity when compared to the same amount of naked DNA (50 mg). The liver luciferase levels in mice receiving the lipoplex via portal vein injection (25 mg DNA) after partial hepatectomy were markedly higher than those with the injection of 100 mg plasmid DNA in lipoplexes without partial hepatectomy. Dose-dependent levels of luciferase activity were obtained by injection of 25-75 mg DNA complexed with PCL-Chol cationic liposomes, whereas the transgene expression in other organs, such as lungs, spleen and kidneys remained relatively constant. In summary, our unique polymerized cationic liposomes are effective transfection agents, and they promote a high-level gene transfer to the mouse liver. To our knowledge, this is the first example of a high level of in vivo gene delivery mediated by serum-resistant, polymerized cationic liposomes (PCL-Chol).
Thyroid hormone injection promotes PCL-Cholmediated gene delivery to the liver
We explored a non-invasive approach to stimulate hepatocyte regeneration, thyroid hormone T 3 injection. T 3 was injected subcutaneously (4 mg/kg) 3 days before the lipoplex administration through either portal vein or tail vein. The transgene expression (luciferase activity) is shown in Figure 4 . It is evident that T 3 pretreatment 
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Liu et al resulted in a marked increase in luciferase activity in the liver (166-fold increase with tail vein injection, and 44-fold increase with portal vein injection), without significant increase in other organs (lungs, spleen and kidneys). The luciferase level was similar to the highest levels in mice with partial hepatectomy as shown in Figure 3 . The luciferase level in the liver from mice receiving portal vein injection after T 3 pretreatment was only 2.8-fold higher than with tail vein injection; that difference was not as great as when partial hepatectomy was performed before the lipoplex administration. This finding suggests that systemic administration of lipoplex may be adequate to achieve a high level of liposomemediated gene transfer when thyroid hormone is provided prior to the lipoplex administration.
Liver DNA synthesis after partial hepatectomy or thyroid hormone injection
We employed the 5-bromo-2 0 -deoxyuridine (BrdU) in vivo incorporation assay to compare the extent of DNA synthesis in the liver after partial hepatectomy or T 3 pretreatment. Two hours after intraperitoneal injection of BrdU, mice were killed for the collection of liver specimens. The liver sections were stained with antiBrdU monoclonal antibodies conjugated with fluorescein. As shown in Figure 5 , approximately 2% of hepatocytes were found to be BrdU positive in control mice. Both partial hepatectomy and T 3 injection led to approximately 18-22% of the hepatocytes entering a proliferation cycle as indicated by in vivo BrdU incorporation. The percentage of BrdU-positive cells in the liver 48 h after partial hepatectomy was higher than that in the liver after T 3 injection (Po0.05), but there was no significant difference at 72 h between partial hepatectomy and T 3 administration ( Figure 5 ). These findings indicate that T 3 administration gave rise to a level of hepatocyte regeneration similar to partial hepatectomy, which has been the standard, but invasive, approach to stimulate liver regeneration for gene delivery with viral or non-viral vectors.
Comparison of liver gene transfer efficiency by three different cationic liposome formulations
Three cationic liposomal formulations PCL-Chol, DO-TAP-Chol and DOTAP-DOPE generated in the manner as described in a previous section, were complexed with 100 mg plasmid DNA, and the resulting lipoplexes were injected via portal vein 1 or 3 days after subcutaneous injection of T 3 . Liver luciferase activity was determined 1 day after the administration of the lipoplexes. As shown in Figure 6 , there was no significant difference in the low level of liver luciferase activity 1 day after injection of the three different lipoplexes via portal vein without prior T 3 administration. However, the liver luciferase activity in mice receiving the PCL-Chol-DNA complex injection 1 day after T 3 injection was significantly higher than those receiving either DOTAP-Chol-DNA (three-fold) or DO-TAP-DOPE-Chol (four-fold) (Po0.01). Moreover, the liver luciferase activity in mice receiving these three cationic liposome formulations with DNA complexes 3 days after the same dose of T 3 injection was generally higher than 1 day after T 3 injection. PCL-Chol displayed a better transfection efficiency (2.4-fold increase in luciferase activity) in mouse liver than DOTAP-DOPE in this set of animal experiments (Po0.01).
Repeated injections of lipoplexes via an indwelling catheter in the portal vein for extended gene expression
In order to administer lipoplexes repeatedly, we placed an indwelling catheter in the portal vein of mice. Three Liposome-mediated liver gene delivery Liu et al days after subcutaneous injection of T 3 (4 mg/kg), a surgical procedure was performed to place an indwelling catheter in the portal vein. The first lipoplex (PCL-Chol-DNA, 100 mg plasmid DNA) was injected in 300 ml volume immediately after the completion of the catheter placement. Then, 1 day after the first lipoplex injection, a second dose of T 3 was given, and the second bolus of the lipoplex was administrated 2 days after the first lipoplex injection. Luciferase activity in the liver was measured day 3 to day 5 after the first lipoplex injection. As shown in Figure 7 , luciferase activity (RLU/mg protein) in the liver declined after the second injection of lipoplex (day 3 to day 5). Without a second injection of T 3 , luciferase activity in the liver on day 3 or 1 day after the second bolus of lipoplex administration was maintained at a level similar to that after the first bolus (see the bars for the group of T 3 +PCL-DNA-PV in Figure 4) . When a second dose of T 3 was given 1 day before the second bolus of lipoplex, the luciferase activity in the liver 2 days after the second bolus (day 4 after the first bolus) remained at a level similar to that after the first bolus. Thus, it is evident that multiple lipoplex injections can be given through an indwelling catheter in the portal vein, and that transgene expression can be maintained with repeated injections of lipoplexes. Repeated T 3 injections were required to maintain the extended transgene expression at a high level.
Discussion
To our knowledge, the present study is the first demonstration that polymerized liposomes generated with PCL and Chol are stable in blood when injected intravenously, and are a useful formulation for gene transfer, with markedly enhanced reporter gene delivery to the liver when the lipoplexes are administered via portal vein. We generated the liposomes according to our previous in vitro experiments which showed that incorporation of Chol in the formulation at a molar ratio of 3:1 led to a similar transfection efficiency as Lipofectamine s in a hepatoma line, and that this formulation displays a low level of cytotoxicity and is serum resistant. 14 We chose Chol as the neutral lipid because a recent study showed that incorporation of Chol in cationic liposomes, instead of DOPE, reduced interactions between cationic liposome-DNA complexes and erythrocytes, and improved in vivo gene delivery efficiency. 15 Our formulation bound to plasma proteins at a very low level, as evidenced by very low radioactivity in precipitated plasma proteins from mice injected with PCL-Chol compared to DOTAP-Chol or DOTAP-DOPE. Although there is a possibility that [ 3 H]-cholesterol which was employed for the liposome labeling may leave liposomes and incorporate into lipoproteins, this finding is consistent with our data from in vitro experiments as reported previously, 14 and further confirms that polymerization of cationic lipids is an efficient approach to overcome the formation of aggregates of cationic lipids and plasma proteins when they are administered intravenously. Factors that caused an early clearance of PCL-Chol liposomes from the plasma as indicated by a low total plasma radioactivity in mice injected intravenously with PCL-Chol are not known. It is tempting to speculate that the early clearance may be partially attributed to the increased liver accumulation of the liposomes as evidenced by higher radioactivity (cpm/100 mg) in the liver from mice injected with PCL-Chol compared to those injected with DOTAP-Chol or DOTAP-DOPE (Figure 1, lower panel) . Although the size range of three formulations was the same prior to complexing with plasmid DNA, it is quite possible that the DOTAP formulations aggregated in the blood stream and that this increased aggregation led to limited uptake by the liver. The PCL-Chol formulation probably remained unaggregated and thus could be taken by the liver. Our formulation of PCL-Chol liposomes also forms stable complexes with plasmid DNA at a charge ratio of 1:1 (positive charges from cationic lipid to negative charges from DNA molecules). This formulation thus requires less cationic lipids to form lipoplexes than does a higher charge ratio of lipoplexes for the same amount of plasmid DNA. 
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For liver gene delivery, in addition to generating liverspecific liposomes by labeling them with asialoglycoprotein receptor ligands, such as asialofetuin or steylglucoside, 16, 17 portal vein administration of lipoplexes has been shown to be a more effective approach than systemic administration. 4 The present study also showed that a one-log level increase (2.4 Â 10 4 versus 2.4 Â 10 3 RLU/mg protein) in luciferase activity was achieved when lipoplexes were administered via portal vein compared to tail vein injection. This gene transfer efficiency was markedly improved by partial hepatectomy prior to the lipoplex administration. As shown in Figure 3 , a much higher and dose-dependent level of liver luciferase activity was detected in the mice receiving plasmid DNA with PCL-Chol liposomes via portal vein injection 2 days after partial hepatectomy. The luciferase levels were much higher with 25-75 mg of plasmid DNA than when mice received 100 mg of plasmid DNA without partial hepatectomy. Our in vivo BrdU incorporation assay documented that two days after the partial hepatectomy, 22% of the hepatocytes were BrdU positive, indicating that a large proportion of parenchymal cells entered a proliferation cycle. 18 This finding further confirmed that hepatocyte regeneration plays a crucial role in achieving a high level of transgene expression in liposome-mediated gene delivery. It has been shown that permeability of the nuclear pore complexes is cell cycle dependent. 19 We speculate that proliferating hepatocytes increase their nuclear pore permeability, which allows more plasmid DNA to be transferred into the nucleus, and that episomal plasmid DNA can actively be transcribed with a CMV promoter.
Partial hepatectomy is an invasive approach to stimulate liver regeneration and is thus not ideal for clinical gene delivery, although ex vivo gene delivery to hepatocytes by retroviral vector has been performed in clinical gene therapy trials. 20 Therefore, for clinical applications of liposome-mediated gene delivery, a non-invasive approach that leads to marked hepatocyte proliferation is required. It has been reported recently that thyroid hormone, specifically T 3 , which is used for the treatment of hypothyroidism, and is well tolerated in a clinical setting, causes a repeatable surge of DNA synthesis in the intact livers of euthyroid rats 21 and can stimulate repopulation of transplanted hepatocytes in rats. 22 Pretreatment with thyroid hormone and keratinocyte growth factor significantly enhanced rat hepatocyte proliferation and enabled retroviral gene transfer through systemic administration. 23 We have tested the effects of T 3 on PCL-Chol-mediated gene delivery to the liver. As shown in Figure 4 , T 3 pretreatment resulted in a marked increase in luciferase activity in the liver (166-fold with tail vein injection, and 44-fold with portal vein injection), without significant increase in other organs (lungs, spleen and kidneys). The luciferase level was very close to the highest levels in mice with partial hepatectomy as shown in Figure 3 . An in vivo BrdU incorporation assay demonstrated that 19.0 7 0.5% of hepatocytes were positive for anti-BrdU staining in the frozen liver sections 3 days after the T 3 injection. T 3 acts via its nuclear receptors which are ligand-dependent nuclear transcription factors, 24 causes an increase in cyclin D 1 mRNA and protein levels at an early phase of hepatocyte regeneration in rats, and in turn leads to transition of G 1 phase to the S phase of the cell cycle. 25 Thus, T 3 pretreatment may be considered as a potential non-invasive approach in the stimulation of hepatocyte proliferation for gene delivery experiments.
Our results, as shown in Figure 6 , demonstrate that without T 3 pretreatment, the three cationic liposome formulations displayed a similar low level of gene transfer efficiency in the liver after the administration of lipoplexes through the portal vein, and that pretreatment of T 3 enhanced different formulations of cationic liposome-mediated gene delivery to the liver. A 3-4-fold increase in luciferase activity was seen in PCL-Cholmediated gene delivery to the liver 1 day after T 3 pretreatment in comparison with DOTAP-Chol or DOTAP-DOPE, and thus it appears that PCL-Chol formulation may be superior to DOTAP-Chol or DO-TAP-DOPE based perhaps on its lower tendency to bind to plasma proteins.
Liposome-mediated in vivo gene delivery has been limited by transient expression of the transgene. To treat liver disease, such as liver injury, fibrosis, genetic deficiency or tumors, an extended expression of the functional gene is required to achieve therapeutic effects. We previously established a technique to place an indwelling catheter in the portal vein of mice for multiple injections of a recombinant SV40 vector. 26 The catheter can be maintained in the vessel for more than 1 month without significant adverse effects. The technique was employed for liposome-mediated gene delivery in the present study. As shown in Figure 7 , luciferase activity in the liver declined in the days following the second injection of lipoplex. When a second dose of T 3 was given 1 day before the second bolus of lipoplex, the luciferase activity in the liver 2 days after the second bolus was boosted to significantly higher levels. Thus, it appears that repeated injections of lipoplex can be given though an indwelling catheter in the portal vein, and that transgene expression can be maintained, at least for the short term, with repeated injections of lipoplexes when liver regeneration is maintained.
In conclusion, our findings demonstrate that the polymerized cationic liposomes are very stable when administered intravenously, are an effective agent for in vivo liver gene delivery when the lipoplexes are administered via a portal vein route, and may be superior to other commonly used cationic liposome formulations. Moreover, thyroid hormone administration offers a non-invasive approach to enhance liposomemediated liver gene delivery. Placement of an indwelling catheter in the portal vein provides a feasible route of repeated administration of lipoplexes for extended gene transfer to the liver.
Materials and methods

Chemicals
DOTAP and DOPE were purchased as a chloroform solution from Avanti Polar Lipids (Alabaster, AL, USA). Chol and T 3 were purchased from Sigma Chemical Company, St. Louis, MO, USA. Poly(cationic lipid) was synthesized according to a method described previously. 13 27 was kindly provided by Dr James G Hecker, Department of Anesthesiology, UC Davis School of Medicine, and pEGFP-C1 was from Clontech Inc., Palo Alto, CA, USA. Both plasmid vectors have a CMV promoter and were transformed (amplified) into competent Escherichia coli cells from Gibco Life Science Technologies, Grand Island, NY, USA. The plasmid DNA was extracted from overnight cultures of the competent cells and purified by affinity chromatography with a plasmid extraction kit from Qiagen, Inc., Valencia, CA, USA. The quality of the DNA was determined by UV spectroscopy and agarose gel electrophoresis after cleavage by specific restriction endonucleases. 14 The DNA concentration was quantitated spectrophotometrically.
Generation of liposomes and formation of cationic liposome-DNA complexes PCL-Chol, DOTAP-Chol and DOTAP-DOPE were generated in a molar ratio of 3:1 as described previously 14 and their size was measured before mixing with plasmid DNA using a laser-based, submicron particle size analyzer from Beckman Coulter, Inc., as previously described. 28 [ 3 H]-Cholesterol was added into the lipid mixture before hydration according to a method described previously. 28 The size distribution of three formulations of cationic liposomes before mixing with plasmid DNA was between 200 and 300 nm. The mixture of cationic liposomes with plasmid DNA was performed prior to use in a charge ratio of 1:1 according to a method described by Templeton et al. 2 In brief, DNA solution at a concentration of 1 mg/ml was added dropwise to the liposome suspension and mixed by pipeting. The complexes were kept at room temperature until injection.
Animal experiments
For biodistribution experiments, three IRC mice in each time point were injected intravenously with 200 ml of cationic liposome suspension via tail vein. 30, 120 and 240 min after the injection, the animals were anesthetized for collecting blood from the inferior vena cava, and tissue from the liver, heart, lungs, spleen and kidneys. RBC were separated from 600 ml of anticoagulated blood. Proteins in the plasma were precipitated by 50% TCA. The radioactivity in RBC, precipitated plasma proteins and the plasma before the precipitation was determined. The organ distribution was calculated and expressed as cpm/100 mg tissue.
Mice were injected with a maximum of 300 ml lipoplexes via tail vein. For portal vein injection, animals were anesthetized by pentobarbital (60 mg/kg, i.p.).
After a midline incision was performed, and exposure of the portal vein, a direct injection of lipoplexes was made with a 31 gauge needle. For partial hepatectomy, the front left and right lobes were ligated and dissected. For placement of an indwelling catheter in the portal vein, a protocol described by Peeters et al 29 was followed. In brief, a short PE10 polyethylene tube, which was inserted into a long silicone tube for tunneling through the abdominal wall, was inserted into the portal vein and fixed with a drop of adhesive gel. The silicone tube was tunneled and had its opening in the animal's back for repeated injections. An injection schedule described in the Results section was followed for the lipoplex administration through the indwelling catheter. T 3 was injected subcutaneously (4 mg/kg) 3 days before the first lipoplex injection and 1 day before the second bolus of lipoplex administration. Organs were collected and frozen in liquid nitrogen until reporter gene assessment was undertaken.
In vivo BrdU incorporation
The in vivo BrdU incorporation assay was performed according to a method described by Frederiks et al. 30 Briefly, 2-3 days after partial hepatectomy or T 3 injection, BrdU at 1.0 mg/mouse. was injected intraperitoneally. Two hours after BrdU injection, the liver specimen was collected and snap frozen in liquid nitrogen for frozen sectioning. The liver sections of 4-6 mm thickness were fixed with absolute methanol and stained with fluorescein-conjugated monoclonal antibodies against BrdU from Roche Molecular Biochemicals, Indianapolis, IN, USA, according to a manual provided by the manufacturer. The sections were examined under a fluorescent microscope and the images were recorded in a digital image system. BrdU-positive cells were counted in 10 fields from each section.
Examination of GFP images
Frozen tissue was sectioned in 10 mm thickness in a Cryostat, fixed in 10% formalin, and sealed with a coverslip using anti-fading mounting medium. The GFP images were visualized under a fluorescent microscope, and recorded in a digital image system.
Luciferase activity assay
Frozen mouse tissues were homogenized and then subjected to three cycles of freeze-thawing according to a method described by Song et al 31 The luciferase activity in 20 ml of tissue homogenate was measured with a luciferase assay kit from Promega Inc., Madison, WI, USA, and in a luminometer from EG&G Wallac, Gaithersburg, MD, USA. The protein content was quantitated by a kit from Bio-Rad Corp., Hercules, CA, USA. The luciferase activity was expressed as RLU/mg protein content in tissue homogenate.
Statistical analysis
Single-factor ANOVA test was employed to analyze the data of biodistribution of cationic liposomes, and comparison of the liver gene transfer efficiency with three different cationic liposome formulations. Newman-Keul tests were used for further multiple comparisons between groups. A Students t-test was used for evaluation of the data of BrdU-positive cells in liver sections from hepatectomized or T 3 -treated mice.
Liposome-mediated liver gene delivery
Liu et al A P-value of less than 0.05 was considered as statistically significant.
